Posted:
A randomized, double-blind, placebo-controlled trial tested whether intratympanic latanoprost improves symptoms in patients with active stage II to III Méniere disease, focusing on hearing, tinnitus, and vertigo outcomes. Participants received either latanoprost (one or three injections) or placebo (one or three injections) via intratympanic injection over a 3-month period.
The primary measure was change in speech discrimination in noise, with secondary measures including hearing thresholds, tinnitus handicap inventory scores, vertigo frequency, and patient-reported symptoms.
Results showed no significant differences between latanoprost and placebo groups for any outcome, suggesting that latanoprost is not more effective than placebo for improving hearing, tinnitus, or vertigo in this population. Safety findings showed the treatment was well-tolerated.
Learn more here.
